Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Bayer Japan Unit Sells iPS Cell Technology Patents To Izumi Of U.S.

This article was originally published in PharmAsia News

Executive Summary

Japan's Bayer Yakuhin says its parent company plans to sell patents it holds on its induced pluripotent stem cells to a U.S. bioventure, iZumi Bio. The technology patents are based on the cell line technology invented by a Japanese researcher, now a researcher at iZumi. The sale by Bayer Yakuhin, a subsidiary of German drug maker Bayer AG, includes both domestic and international patents for the technology. The price was not disclosed. (Click here for more - a subscription may be required

Table

View full table

Tags:
Latest Headlines

JLABS Korea, The Next Evolution Of J&J’s Innovation Model

Newron’s Add-On Treatment Shows Promise In Newly Popular Schizophrenia Field

Lilly Mounjaro, Zepbound Supply Issues Persist Amid Strong Growth

Podcast: Facilitating Patient Monitoring in CAR-T Development

See All
UsernamePublicRestriction

Register

SC070780

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By